Right heart failure after left ventricular assist device implantation: early and late. 2012

Guy A MacGowan, and Stephan Schueler
Departments of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK. guy.macgowan@nuth.nhs.uk

OBJECTIVE To review recent publications on right heart failure developing early and late after implantation of left ventricular assist devices (LVAD). RESULTS Whereas use of the newer continuous flow devices is associated with improved outcomes, right heart failure remains a considerable challenge. Recent studies have provided good evidence about predicting right heart failure early after LVADs, though how to predict right heart failure late after LVAD is still unclear as most studies in this area are small single centre experience studies. With respect to medical therapies for treating right heart failure, there is evidence for the use of both nitric oxide and the phosphodiesterase type 5 inhibitor sildenafil in carefully selected patients with secondary pulmonary hypertension who undergo implantation of LVADs. CONCLUSIONS Despite improved outcomes, right heart failure remains a significant challenge to selecting and managing patients with LVADs, though we do have clearer evidence now for predicting early right heart failure, and treating it in those patients with secondary pulmonary hypertension.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004868 Equipment Failure Failure of equipment to perform to standard. The failure may be due to defects or improper use. Defects, Equipment,Device Failure,Failure, Equipment,Malfunction, Equipment,Medical Device Failure,Misuse, Equipment,Device Failure, Medical,Device Failures, Medical,Failure, Medical Device,Failures, Medical Device,Defect, Equipment,Device Failures,Equipment Defect,Equipment Defects,Equipment Failures,Equipment Malfunction,Equipment Malfunctions,Equipment Misuse,Equipment Misuses,Failure, Device,Failures, Device,Failures, Equipment,Malfunctions, Equipment,Misuses, Equipment
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006353 Heart-Assist Devices Small pumps, often implantable, designed for temporarily assisting the heart, usually the LEFT VENTRICLE, to pump blood. They consist of a pumping chamber and a power source, which may be partially or totally external to the body and activated by electromagnetic motors. Artificial Ventricle,Heart Assist Device,Heart Ventricle, Artificial,Pumps, Heart-Assist,Vascular-Assist Device,Vascular-Assist Devices,Ventricle-Assist Device,Ventricular Assist Device,Artificial Heart Ventricle,Artificial Heart Ventricles,Artificial Ventricles,Assist Device, Heart,Assist Device, Ventricular,Assist Devices, Heart,Assist Devices, Ventricular,Device, Heart Assist,Device, Heart-Assist,Device, Vascular-Assist,Device, Ventricle-Assist,Device, Ventricular Assist,Devices, Heart Assist,Devices, Heart-Assist,Devices, Vascular-Assist,Devices, Ventricle-Assist,Devices, Ventricular Assist,Heart Assist Devices,Heart Ventricles, Artificial,Heart-Assist Device,Heart-Assist Pump,Heart-Assist Pumps,Pump, Heart-Assist,Pumps, Heart Assist,Vascular Assist Device,Vascular Assist Devices,Ventricle Assist Device,Ventricle, Artificial,Ventricle, Artificial Heart,Ventricle-Assist Devices,Ventricles, Artificial,Ventricles, Artificial Heart,Ventricular Assist Devices
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D058986 Phosphodiesterase 5 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 5. PDE-5 Inhibitor,PDE5 Inhibitor,Phosphodiesterase 5 Inhibitor,Phosphodiesterase Type 5 Inhibitor,PDE-5 Inhibitors,PDE5 Inhibitors,Phosphodiesterase Type 5 Inhibitors,5 Inhibitor, Phosphodiesterase,Inhibitor, PDE-5,Inhibitor, PDE5,Inhibitor, Phosphodiesterase 5,Inhibitors, PDE-5,Inhibitors, PDE5,Inhibitors, Phosphodiesterase 5,PDE 5 Inhibitor,PDE 5 Inhibitors

Related Publications

Guy A MacGowan, and Stephan Schueler
January 2024, Expert review of medical devices,
Guy A MacGowan, and Stephan Schueler
March 2023, ASAIO journal (American Society for Artificial Internal Organs : 1992),
Guy A MacGowan, and Stephan Schueler
December 2023, Journal of thoracic disease,
Guy A MacGowan, and Stephan Schueler
March 2014, Journal of thoracic disease,
Guy A MacGowan, and Stephan Schueler
July 2023, Indian journal of thoracic and cardiovascular surgery,
Guy A MacGowan, and Stephan Schueler
January 2013, ASAIO journal (American Society for Artificial Internal Organs : 1992),
Guy A MacGowan, and Stephan Schueler
January 2015, Methodist DeBakey cardiovascular journal,
Copied contents to your clipboard!